- Case Report
- Open Access
Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)–CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report
© Jiang et al.; licensee BioMed Central Ltd. 2014
- Received: 28 August 2013
- Accepted: 10 March 2014
- Published: 12 March 2014
Pegylated interferon combined with ribavirin treatment is an effective therapy for chronic hepatitis C viral infection. However, pegylated interferon combined with ribavirin is associated with various adverse reactions. Severe thrombocytopenia is a life-threatening side effect of interferon therapy that can lead to bleeding. It is generally understood that the inosine triphosphatase-CC genotype does not have a significantly lower reduction by pegylated interferon combined with ribavirin in the mean platelet counts compared with the AA/CA genotype. We report a case of severe thrombocytopenia that developed in a patient with chronic hepatitis C treated with pegylated interferon combined with ribavirin in spite of having the inosine triphosphatase-CC genotype.
A 57-year-old female had been diagnosed as having HCV infection in 2008. The inosine triphosphatase gene showed one single nucleotide polymorphism (rs1127354) C/C (major homozygous) and the IL28B gene showed single nucleotide polymorphism (rs8099917 T/T, rs11881222 T/T) (major homozygous). The patient was treated with pegylated interferon 180 μg once a week combined with ribavirin 600 mg per day from April 2011. The hepatitis c virus ribonucleic acid turned negative 9 weeks after treatment with pegylated interferon combined with ribavirin. During the therapy, the platelet count remained above 8.0 × 104/μl for about 9 months. In January 2012, the platelet count was 6.8 × 104/μl. In February 2012, the 44th week from the beginning of the treatment, a sudden decrease in the platelet count to 0.8 × 104/μl was observed. After prednisolone was administered, the platelet count increased. Finally the platelet count had risen above normal range.
We should pay careful attention in the differential diagnosis for patients with the inosine triphosphatase-CC genotype because, although rare, severe thrombocytopenia could occur.
- Hepatitis C
- Pegylated interferon
Chronic infection with hepatitis C virus (HCV) affects up to 170 million individuals worldwide  and may lead to progressive hepatic fibrosis and cirrhosis, with risk of liver failure and hepatocellular carcinoma. Pegylated interferon (PEG-IFN) combined with ribavirin (RBV) treatment (PEG-IFN/RBV) is an effective therapy for chronic HCV infection. However, PEG-IFN/RBV is associated with various adverse reactions. Some of these side effects are mild, such as flu-like symptoms. Some others can be very severe and even lead to lethal consequences . Severe thrombocytopenia is a life-threatening side effect of interferon therapy that can lead to bleeding, and even death, if diagnosis and treatment are not adequately given. Therefore, how to identify the possibility of thrombocytopenia early is critical for patients treated with PEG-IFN/RBV.
Recently, genome-wide association studies have identified that the genetic variant of rs1127354 single nucleotide polymorphisms (SNPs) in the inosine triphosphatase (ITPA) gene, which encodes a protein that hydrolyses inosine triphosphate (ITP), has been found to be associated with thrombocytopenia. The ITPA-AA/CA genotype was independently associated with a higher degree of reduction in platelet counts at 4 weeks as well as protection against the reduction of hemoglobin in patients treated with PEG-IFN/RBV [3–5], while the CC genotype had significantly lower reduction in the mean platelet counts compared with the AA/CA genotype . Here, we report a case of severe thrombocytopenia that developed in a patient with chronic hepatitis C treated with PEG-IFN-α2a plus ribavirin in spite of having the ITPA-CC genotype.
The patient’s laboratory findings prior to receiving treatment
404 × 104
16.7 × 104
On admission, the blood pressure, temperature and pulse of the patient were normal. Her white blood cell and neutrophil values were also in the normal range. And there was no evidence of bacterial, viral, or other microorganism infection. Purpura were noted on both lower limbs and her trunk. The white blood cell count was 3000/μl, the red blood cell count was 3.14 × 106/μl, hemoglobin was 11.2 g/dl, but the platelet count had decreased to 1.1 × 104/μl. The liver function and coagulation function were normal. But the PAIgG was elevated to 180 ng/L (normal range, 9-25 ng/L).
Based on these results, she was diagnosed as having immune-mediated thrombocytopenia caused by the PEG-IFN-α-2a therapy. Therefore, the PEG-IFN/RBV was discontinued, but the platelet count remained below 1.0 × 104/μl. We confirmed that her anti-Helicobacter pylori was positive but did not perform eradication therapy. In March 2012, 60 mg of prednisolone were administered orally. After starting corticosteroid therapy, the platelet count increased gradually. Then the prednisolone was gradually tapered down by 10 mg every 4 days, the platelet count gradually rose above 10 × 104/μl, and the PAIgG was decreased to 80 ng/L. When the prednisolone dosage decreased to 30 mg per day orally, she was discharged. The prednisolone was gradually tapered off, and the platelet count returned to normal (Figure 2). Prednisolone was discontinued in May 2012. Her platelet count remained normal during the follow-up. And HCV RNA has never been detected since. She was diagnosed as having a sustained virologic response (SVR) 6 months later.
To our knowledge, this is the first case report to assess the relationship between severe thrombocytopenia that developed in a patient treated with PEG-IFN/RBV and that patient having the ITPA genotype. It is a worthwhile case because, in spite of having the ITPA-CC genotype, the patient developed severe thrombocytopenia caused by the PEG-IFN/RBV treatment.
It is generally thought that an ITPA genetic variant is independently associated with reduction in the mean platelet counts for weeks 2, 4, 8, and 12 ; while it is also associated with the reduction of hemoglobin for those same weeks caused by the RBV . On the other hand, IL28B genetic variant strongly associated with the response to PEG-IFN/RBV . Patients with the IL28-TT genotype exhibit higher prevalence of virologic response compared to those with IL28B-TC/CC. When we began to administer the PEG-IFN/RBV treatment, we expected the possibility of SVR and had been cautious of the reduction of hemoglobin because the patient had the IL28B-TT and ITPA-CC genotypes. Indeed, she achieved negative HCV RNA after only 9 weeks administration of PEG-IFN/RBV and her hemoglobin level had gradually decreased to a maximum of 9.6 g/dl. The side effects of PEG-IFN/RBV treatment are widely known, such as leukopenia, anemia, and thrombocytopenia. Hematologic abnormalities often lead to dose reduction and premature withdrawal from therapy in 10%–14% of patients . It is not rare that mild-to-moderate thrombocytopenia is caused by PEG-IFN/RBV, and it has been attributed to a direct inhibition of stem cell proliferation and differentiation in the bone marrow . Yamane et al. reported IFN-α directly inhibited cytoplasmic maturation and platelet production but not proliferation or endomitosis in human primary megakaryocytes . However, severe thrombocytopenia (platelet counts less than 2.5 × 104/mm3) during interferon therapy is rare, and it is a life-threatening side effect.
In the present case, in the early period of administration (within 12 weeks) of PEG-IFN/RBV, mild-to-moderate thrombocytopenia was caused by the treatment, but the platelet count remained at or around 10 × 104/μl for 9 months. Li et al. reported in their review of severe thrombocytopenia induced by IFN-α in 17 patients  that the median onset time from the administration of IFN-α/PEG-IFN-α treatment was 3.6 months (range, 1–36 months), and the patients could recover by discontinuing the IFN-α/PEG-IFN-α and administering an immunosuppressant. It is noteworthy that they reported that 16 patients (94%) had reached SVR in spite of a short period of IFN-α administration. Generally, PEG-IFN/RBV can achieve rates of an SVR of less than 50% in patients with HCV genotype 1. Therefore, there might be a correlation between severe thrombocytopenia and SVR that is caused by PEG-IFN/RBV therapy.
It is necessary to consider the mechanism in the present case of this severe thrombocytopenia. The IFN-α treatment is considered an immune-modulator and increases the risk for immune thrombocytopenia purpura in patients with hepatitis C , but the mechanism of IFN-induced autoimmune thrombocytopenia is unclear . IFN-α/PEG-IFN-α can induce the production of autoantibody against thrombocytes, such as platelet antibody, which can lead to immune-mediated thrombocytopenia . This situation is critical and may sometimes result in death. IFN can enhance the expression of major histocompatibility class I antigens and promote the production of IL-1 (interleukin 1) and TNF-α (tumor necrosis factor alpha). The over expression of these cytokines can induce autoimmune disease . It is observed that higher Th1 (T helper 1) cell reactivity with platelets is related to idiopathic thrombocytopenic purpura (ITP) patients. PEG-IFN can increases IFN-γ secretion and improve CD4 T cell response in HCV-infected patients . This may be one of the reasons of autoimmune thrombocytopenia during PEG-IFN treatment . Recently, it is considered that autoimmune thrombocytopenia is associated with imbalance of Treg/Th17 cells . But, to our knowledge, there are no data in PEG-IFN induced thrombocytopenia.
Regarding the treatment, we discontinued PEG-IFN/RBV after we diagnosed IFN-induced autoimmune thrombocytopenia and administrated 60 mg of prednisolone first. Li et al. reported that early administration of immunosuppressant was an effective therapy for IFN-α induced severe thrombocytopenia .
Finally, it was considered that this case was “possible” drug-induced immune thrombocytopenia based on criteria and level of evidence for establishing a causative relationship in drug-induced thrombocytopenic purpura by George et al. [16, 17]. It is the reason that this case meets only their first criteria and evidence: therapy with the candidate drug preceded the thrombocytopenia, and recovery from thrombocytopenia was complete and sustained after discontinuation of therapy.
The 2011 practice guideline by the AASLD (American Association for the Study of Liver Diseases) recommended that IL28B genotype variants are robust pretreatment predicators of the SVR to PEG-IFN/RBV in patients with genotype 1 chronic HCV infection . In thrombocytopenia caused by PEG-IFN/RBV, there is a tendency that patients with the ITPA-CC genotype are considered to be less at risk than those with the ITPA-CA/AA genotype. However, the newest treatment (PEG-IFN/RBV and protease inhibitors) might weaken this tendency. Therefore, this case of severe thrombocytopenia that developed in a patient with chronic hepatitis C treated with PEG-IFN/RBV in spite of the patient having the ITPA-CC genotype should be kept in mind.
In conclusion, it is generally understood that the CC genotype had significantly less reduction in the mean platelet counts compared with the AA/CA genotype. However, we should pay careful attention in the differential diagnosis for patients with the ITPA-CC genotype because, although rare, severe thrombocytopenia could occur.
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank Atsuko Takeuchi and Akitaka Shibuya of Kitasato University School of Medicine for their assistance of genome sequence techniques. We also thank Professor Yasuhito Tanaka, Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences and Robert E. Brandt (Founder, CEO, and CME, of MedEd Japan) for editing the manuscript.
- Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011, 54: 1433-1444. 10.1002/hep.24641.PubMedPubMed CentralView ArticleGoogle Scholar
- Hoofnagle JH, Seeff LB: Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006, 355: 2444-2451. 10.1056/NEJMct061675.PubMedView ArticleGoogle Scholar
- Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB: ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature. 2010, 464: 405-408. 10.1038/nature08825.PubMedView ArticleGoogle Scholar
- Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG: Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010, 139: 1181-1189. 10.1053/j.gastro.2010.06.016.PubMedPubMed CentralView ArticleGoogle Scholar
- Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsuhashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M: Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet. 2011, 20: 3507-3516. 10.1093/hmg/ddr249.PubMedView ArticleGoogle Scholar
- Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009, 41: 1105-1109. 10.1038/ng.449.PubMedView ArticleGoogle Scholar
- Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009, 360: 1839-1850. 10.1056/NEJMoa0807650.PubMedView ArticleGoogle Scholar
- Hoofnagle JH: Thrombocytopenia during interferon alpha therapy. JAMA. 1991, 266: 849-PubMedView ArticleGoogle Scholar
- Yamane A, Nakamura T, Suzuki H, Ito M, Ohnishi Y, Ikeda Y, Miyakawa : Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood. 2008, 112: 542-550. 10.1182/blood-2007-12-125906.PubMedView ArticleGoogle Scholar
- Li L, Han DK, Lu J: Interferon-α induced severe thrombocytopenia: a case report and review of the literature. World J Gastroenterol. 2010, 16: 1414-1417. 10.3748/wjg.v16.i11.1414.PubMedPubMed CentralView ArticleGoogle Scholar
- Emilia G, Longo G, Luppi M, Gandini G, Morselli M, Ferrara L, Amarri S, Cagossi K, Torelli G: Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood. 2001, 97: 812-814. 10.1182/blood.V97.3.812.PubMedView ArticleGoogle Scholar
- Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U: Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother. 1999, 53: 242-254. 10.1016/S0753-3322(99)80095-X.PubMedView ArticleGoogle Scholar
- Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW: Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002, 123: 1070-1083. 10.1053/gast.2002.36045.PubMedView ArticleGoogle Scholar
- Sagir A, Wettstein M, Heintges T, Haussinger D: Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci. 2002, 47: 562-563. 10.1023/A:1017964002402.PubMedView ArticleGoogle Scholar
- Johnsen J: Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program. 2012, 2012: 306-312.PubMedGoogle Scholar
- George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T: Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998, 129: 886-890. 10.7326/0003-4819-129-11_Part_1-199812010-00009.PubMedView ArticleGoogle Scholar
- Aster RH, Bougie DW: Drug-induced immune thrombocytopenia. N Engl J Med. 2007, 357: 580-587. 10.1056/NEJMra066469.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.